SAN DIEGO, March 30, 2017 -- Medical Marijuana, Inc. ( MJNA ), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds®Brasil will hold the Country's first-ever symposium dedicated to providing the Brazilian medical community with information about the medical value of cannabidiol (CBD) and how to legally import CBD into the country for patients.
The Company's first symposium on medical cannabis, which will take place on April 4 in Rio de Janeiro, is part of the Company's goal to educate health professionals on the therapeutic uses of cannabis and will feature renowned medical experts and pioneers in the field like Dr. Saul Garza Morales, pediatric researcher and neurologist in Mexico and Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. Both will share on the specific therapeutic benefits of CBD, as well as gaining access to medical cannabis for improving health and quality of life.
Dr. Garza will also share the positive results of a recent study he conducted on the effects of Medical Marijuana, Inc.'s Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy, in which 86 percent of the 39 patients he studied experienced statistically significant (greater than 50%) reduction in motor seizures. Seventeen percent of the children were fully seizure free for a 4-month period, which is quite remarkable for this advanced epilepsy population ("the worst of the worst," according to Dr Garza).
"I'm looking forward to participating in this forward-thinking symposium held by HempMeds® Brasil, which serves an invaluable purpose to those in Brazil who suffer needlessly in silence by helping the gain access to CBD hemp oil products," said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. "We are proud of our Company for having educated thousands of doctors and patients alike on medical cannabis and are dedicated to not only continuing educating health professionals on the plethora of benefits that medical cannabis provides to treat several types of indications, but also how to best gain access to these products so that we can work together in strengthening the lives and livelihoods of those we serve."
"With the results of two studies performed in Mexico utilizing RSHO-X, we are thrilled to see the scientific validation of our proprietary products," Dr. Titus continued. "While other groups may offer CBD, we believe that the recap of the recent study by Dr. Saul Garza Morales puts us in a space where the medical community can potentially replicate his results with Brazilian and other Latino populations of epilepsy children. It is especially thrilling to note seizure reductions as well as other quality of life improvements for families - all which make their lives much easier. We look forward to ongoing scientific inquiry utilizing our products and this Brazil Symposium will hopefully kick off additional research on the therapeutic benefits of botanical CBD."
In May 2015, HempMeds®Brasil became the first company to offer legal medicinal cannabis products to Brazil after receiving import approval for those suffering from specific medical conditions. The Brazilian government now waives import taxes for RSHO, subsidizes its cost and covers the product under the Country's health insurance. In addition, 2017 marked the first time that Brazil's National Health Surveillance agency ANVISA granted the filling of a prescription for RSHO™ to help patients combat the effects of Autism Spectrum Disorder (ASD), Multiple Sclerosis and Alzheimer's disease.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system. As of 2015 ANVISA has allowed cannabidiol treatments for any medical condition a doctor sees could help the patient. HempMeds® Brasil has had doctor prescriptions for Epilepsy, Parkinson's, Alzheimer's, Cancer, Autism, Multiple Sclerosis and Chronic Pain to date and is working on additional approvals for multiple indications.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P: 888-829- 0070